This HTML5 document contains 164 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n12http://dx.doi.org/10.1016/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q39037126
rdf:type
wikibase:Item
schema:description
artículo científico publicado en 2017 2017年论文 scientific article published on 2 May 2017 научна статия 2017 nî lūn-bûn articolo scientifico 2017年论文 ശാസ്ത്രപ്രബന്ധം​ naučni članak artikulong pang-agham artículu científicu espublizáu en 2017 מאמר מדעי article scientific 2017年論文 teaduslik artikkel 2017년 논문 scientific article published on 2 May 2017 artigo científico article científic 2017年論文 ২ মে ২০১৭-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ scientific article published on 2 May 2017 სამეცნიერო სტატია 2017年論文 2017年论文 scienca artikolo wetenschappelijk artikel articol științific vitskapeleg artikkel tudományos cikk artikull shkencor научни чланак artikel ilmiah artykuł naukowy vetenskaplig artikel article scientifique научни чланак artigo científico 2017年論文 2017年论文 artigo científico научная статья vědecký článek 2017年の論文 επιστημονικό άρθρο videnskabelig artikel 2017年论文 vedecký článok мақолаи илмӣ vitenskapelig artikkel 2017年論文 bilimsel makale 2017年论文 наукова стаття, опублікована в травні 2017 tieteellinen artikkeli مقالة علمية نشرت في 2 مايو 2017 บทความทางวิทยาศาสตร์ bài báo khoa học 2017 թվականի մայիսի 2-ին հրատարակված գիտական հոդված wissenschaftlicher Artikel
p:P577
wds:Q39037126-3D45BFEB-4376-4CD8-9387-FCBBC03C2838
wdt:P577
2017-05-02T00:00:00Z
p:P407
wds:Q39037126-58617C23-A9A0-4D1E-9DBB-0A986B826BD3
wdt:P407
wd:Q1860
p:P2860
wds:Q39037126-11EBC20E-EC8C-4492-9D0A-1CE918C76156 wds:Q39037126-1C156537-C16A-43CA-849F-CB1BEE012DF1 wds:Q39037126-22604959-4138-4296-83F2-AFB8C58A79DA wds:Q39037126-472156FE-B189-4150-BB8C-A37F3B08E9BE wds:Q39037126-4779AE15-2875-401A-B2D4-7057E0836F8F wds:Q39037126-4964D0E1-8910-40FD-A3B5-0F548D97949F wds:Q39037126-6B8CB683-0E80-4D80-BB8D-2EC03EE71BC6 wds:Q39037126-9BCAA9C1-A117-4135-A5A5-AEF07F318D8A wds:Q39037126-4C9A92E5-1F15-4E99-8E7D-389B617E9174 wds:Q39037126-6B7A6E03-F1D9-4121-9245-042DD064C46E wds:Q39037126-B46EFD24-5899-4812-ADEF-A78661E36538 wds:Q39037126-B9CEF0C3-A1F7-4C3C-924D-B8981CED730F wds:Q39037126-A0342996-616D-46FE-B42C-5A43DEE09BEB wds:Q39037126-A0A286A7-0AFB-480F-B74B-CDF48FF6BDC1 wds:Q39037126-DFC7D32D-F2C3-49CF-B63F-60A1B3AB0B91 wds:Q39037126-E33B6FE1-0EB2-4B7F-BDC1-8C28E0DA5D05 wds:Q39037126-C3895E22-0261-4892-91C6-54947550FFBE wds:Q39037126-C9814D50-5D20-4F2C-B385-9C2AC0F8144C wds:Q39037126-CA7FE031-27F0-41AD-850E-F8D056413ED8 wds:Q39037126-FAB12CAA-1046-4BA2-A6B7-17DEE7C4723C wds:Q39037126-FB91C10A-2DE2-4B43-9E21-15C4872B26E1 wds:Q39037126-EDAAD9FA-52EB-4067-AF0F-563BE440AB6F wds:Q39037126-EE78DBFF-6AA4-448E-A2A8-65AD2CF7908A wds:Q39037126-FCDE60FE-D6ED-4826-905D-9DFCDD2E6E0A
wdt:P2860
wd:Q38179262 wd:Q28597146 wd:Q28214393 wd:Q28301815 wd:Q35978349 wd:Q50163305 wd:Q34274829 wd:Q34515717 wd:Q34636135 wd:Q34589564 wd:Q38001992 wd:Q46822930 wd:Q38410899 wd:Q27026332 wd:Q35670282 wd:Q34661723 wd:Q43643108 wd:Q28083004 wd:Q29617817 wd:Q34356285 wd:Q33989952 wd:Q30245459 wd:Q38222224 wd:Q34189543
p:P2093
wds:Q39037126-53536B71-4455-46DB-818E-A99016A1CAA2 wds:Q39037126-BE85CFD1-FE56-4A95-BEED-007F4EB0DDE9 wds:Q39037126-BF32BBB1-A2B6-405E-B31C-5829D5E63E3B wds:Q39037126-2BF23D42-00D5-4239-AFAB-F264B8C431D0 wds:Q39037126-3047D5B8-A8C3-46B5-A233-A11EFA8CF07E wds:Q39037126-EFC4BE4C-8EA7-4C06-9B69-113805B984A8 wds:Q39037126-F662DFFD-D876-460C-81E8-3F9A450D0073
wdt:P2093
Tim Collier Peter Sever Neil Poulter Rory Collins Bjorn Dahlof Ajay Gupta ASCOT Investigators
rdfs:label
Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind exten Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind exten Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind exten
skos:prefLabel
Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind exten Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind exten Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind exten
schema:name
Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind exten Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind exten Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind exten
p:P50
wds:Q39037126-3A177572-A1DE-42D7-BAB1-926204720F7E wds:Q39037126-99046995-AC54-4D0D-8A3F-CDC27882E6E6
wdt:P50
wd:Q77093362 wd:Q88777703
p:P1476
wds:Q39037126-9C308514-8271-4B3E-88F1-DE21CF40E3D4
wdt:P1476
Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind exten
p:P304
wds:Q39037126-1C86E6D2-7E34-4EA1-8BE1-3D0F293D5780
wdt:P304
2473-2481
p:P31
wds:Q39037126-F987F91A-5675-4488-AF01-3B65F1D383F8
wdt:P31
wd:Q13442814
p:P921
wds:Q39037126-A676FE2D-211D-4116-8E19-41183A13B202 wds:Q39037126-E7A204B1-E1BC-4FB5-869C-9E92F89908F5 wds:Q39037126-054904E2-0CB0-493E-BEB8-B6E1A6B0EAF2
wdt:P921
wd:Q108853737 wd:Q269829 wd:Q62562875
p:P698
wds:Q39037126-D5977D95-9BC6-4F2A-A23F-D774DE4B4AAA
wdtn:P698
n10:28476288
wdt:P698
28476288
p:P1433
wds:Q39037126-D5F344A2-EB26-4E2A-BE12-E548C8003F29
wdt:P1433
wd:Q939416
p:P433
wds:Q39037126-4B1BA5E4-7716-42A6-9885-687827267221
p:P478
wds:Q39037126-C3EE3C2A-E638-43D2-89FE-8A1FE9984407
wdt:P433
10088
wdt:P478
389
p:P356
wds:Q39037126-85824104-557F-474E-9E6C-67BE1566FA16
wdtn:P356
n12:S0140-6736(17)31075-9
wdt:P356
10.1016/S0140-6736(17)31075-9